Expression of glycoprotein 90K in human malignant pleural mesothelioma: Correlation with patient survival

Journal of Pathology

Volumn 197, Issue 2, 2002, Pages 218-223

  Strizzi, L ^a   Muraro, R ^b   Vianale, G ^c   Natoli, C ^d   Talone, L ^a   Catalano, A ^b   Mutti, L ^c   Tassi, G ^d   Procopio, A ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c ASL n 11   (Italy)

^d University Hospital   (Italy)

Author keywords

Diagnosis; Glycoprotein 90K; Mesothelioma; Prognosis

Indexed keywords

CELL EXTRACT; CELL PROTEIN; GLYCOPROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATORY INFILTRATE; KAPLAN MEIER METHOD; LINEAR REGRESSION ANALYSIS; LUNG CANCER; MALE; MESOTHELIUM CELL; MOLECULAR WEIGHT; PLEURA DISEASE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN EXPRESSION; SERUM; TISSUE SECTION; TUMOR BIOPSY; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM PROTEINS; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0036265138     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1125     Document Type: Article

References (26)

1. Natural history and epidemiology of malignant mesothelioma
2. Malignant pleural mesothelioma
3. Mesothelioma
4. 90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells
5. Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer
6. A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1 + homosexual men
7. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer
8. Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies
9. A tumor-derived protein which provides T-cell costimulation through accessory cell activation
10. The secreted tumor-associated antigen 90K is a potent immune stimulator
11. Cloning and expression of a mouse macrophage cDNA coding for a membrane glycoprotein of the scavenger receptor cysteine-rich domain family
12. Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV)
13. Establishment of four new mesothelioma cell lines: Characterization by ultrastructural and immunophenotypic analysis
14. Pleural malignant mesothelioma and non-occupational exposure to asbestos in Casale Monferrato, Italy
15. Contemporary management of malignant pleural mesothelioma
16. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
17. Expression of tumor-associated 90K-antigen in human breast cancer: No correlation with prognosis and response to first-line therapy with tamoxifen
18. Biological and immunological aspects of malignant mesothelioma
19. Prognostic value of a novel circulating serum 90K antigen in breast cancer
20. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
21. Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells
22. Distinct categories of immunologic changes in frail elderly
23. Altered cytokine production in the elderly
24. T cell differentiation and cytokine expression in late life
25. Cytokine production pathway in the elderly
26. The immune system in the elderly: I. Specific humoral immunity